Boromycin Gametocytocidal Use for Blocking Malaria Transmission
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial drugs are ineffective against mature Plasmodium falciparum gametocytes, leading to parasite transmission, and there is a need for compounds that can inhibit malaria transmission and treat acute malaria effectively while avoiding resistance and toxicity issues.
Innovation Solution
Boromycin, a bacteriocidal polyether-macrolide antibiotic, is used to inhibit malaria transmission by targeting gametocytes and reducing parasite load quickly, with a favorable toxicity profile and no cross-resistance to chloroquine-resistant strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinin and its derivatives are used to treat malaria, then antimalarial activity is achieved, but hepatotoxicity and anemia occur
Solution Approach 1:
The patent modifies the chemical structure of artemisinin derivatives by changing molecular parameters - specifically introducing a boronic acid group at the C-10 position and varying substituents at C-9 and C-13 positions. This structural parameter change maintains antimalarial activity while reducing hepatotoxicity and anemia effects, as demonstrated by the compound's ability to kill gametocytes without the harmful side effects of conventional artemisinin derivatives.
Solution Approach 2:
The patent creates a composite molecular structure by combining the core artemisinin skeleton with boronic acid functionality and specific substituent groups. This composite structure integrates the beneficial antimalarial properties of artemisinin with the advantageous properties of boronic acid compounds, achieving both efficacy and reduced toxicity simultaneously.
2Reliability
If conventional antimalarial drugs are used, then malaria infection is treated, but drug resistance develops
Solution Approach 1:
The patent employs significant structural parameter changes by introducing boronic acid at C-10 and varying substituents at C-9 and C-13, creating a novel chemical structure that bypasses resistance mechanisms. The compound's unique molecular parameters allow it to effectively kill both sensitive and resistant Plasmodium falciparum strains, including those resistant to artemisinin, chloroquine, and sulfadoxine-pyrimethamine.
Solution Approach 2:
The patent develops a new chemical entity that serves as a disposable solution against drug-resistant malaria. The compound's novel structure ensures it is not affected by existing resistance mechanisms, providing an effective treatment option that can be deployed without concern for pre-existing drug resistance issues.
3Productivity
If existing antimalarial drugs are administered, then parasitic infection is reduced, but severe adverse reactions occur
Solution Approach 1:
The patent achieves favorable parameter changes by modifying the molecular structure to reduce toxicity while maintaining efficacy. The boronic acid substitution at C-10 and specific substituent variations create a compound that clears parasites effectively without causing severe adverse reactions such as hepatotoxicity, anemia, or neurological effects.
Solution Approach 2:
The patent converts the potentially harmful structure-activity relationship of artemisinin derivatives into a benefit by introducing boronic acid functionality. This structural modification transforms the molecule into one that maintains parasite-killing capability while eliminating severe adverse effects, turning a harmful drug profile into a safe and effective treatment.
Data Source
Figure 1
Figure 2
Figure 3A~4
AI summary
The present invention relates to a new compound for the inhibition of the transmission of malaria in humans, a pharmaceutical composition comprising said compound, and a method for the inhibition of the transmission of malaria in humans comprising the administration of said compound.